Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Hanwha Systems has signed a contract worth approximately KRW 197.1B with the Defense Acquisition Program Administration for the KDX-II Performance Improvement Combat System Development Project and 1 other item.
📊 [Key Disclosure Details & Financial Metrics]
- Contract Type: Other Sales/Supply Contract
- Contract Title: KDX-II Performance Improvement Combat System Development Project and 1 other item
- Contract Amount: KRW 197,133,000,000 (KRW 197.1B / VAT included)
- Recent Annual Revenue: KRW 2,453,079,541,922 (Based on 2023 consolidated financial statements)
- Revenue Ratio: 8.04%
- Counterparty: Defense Acquisition Program Administration (DAPA)
- Supply Region: Republic of Korea
- Contract Period: December 13, 2024 – December 31, 2033
- Payment Terms: Payments made in accordance with the Enforcement Decree of the National Treasury Management Act, Government Bidding and Contract Execution Standards, DAPA Advance Payment Conditions, Defense Acquisition Program Act, Regulations on Advance/Progress Payments, and the Enforcement Decree of the State Contracts Act
- Contract Date: December 13, 2024
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Contract Performance Progress and Financial Reflection
This long-term development contract runs through 2033, and the contract amount or duration may change over time based on project developments as noted in the filing. Checking whether the contract proceeds on schedule and how it is reflected in actual financial results and financial position is important for understanding the practical impact of this contract. Relevant execution details and financial impact can be verified through future periodic filings (quarterly, half-year, and annual reports) and subsequent regulatory disclosures.
📢 Disclaimer & Source Notice
Source: This content was newly structured and generated based on official submission data from the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
